瑞舒伐他汀联合贝那普利治疗原发性高血压合并冠心病的效果研究

Effect of rosuvastatin combined with benazepril in the treatment of essential hypertension complicated with coronary heart disease

目的探究瑞舒伐他汀联合贝那普利治疗原发性高血压合并冠心病的效果.方法选择70例2021年2月-2021年10月期间收治的原发性高血压合并冠心病患者,以随机数字表法分为对照组和试验组各35例.使用贝那普利治疗患者纳入对照组,试验组使用贝那普利+瑞舒伐他汀.比较两组患者的血压、血脂、血清生化指标及药物不良反应发生率.结果两组患者治疗前舒张压、收缩压比较,差异无统计学意义(P>0.05);两组治疗后舒张压下降,收缩压下降,与治疗前比较,P<0.05.试验组舒张压、收缩压治疗后均低于对照组,差异有统计学意义(P<0.05).治疗前,两组TC、TG、LDL-C、HDL-C水平比较,差异无统计学意义(P>0.05).治疗后,两组TC、TG、LDL-C均比治疗前降低,HDL-C比治疗前升高,且试验组优于对照组,差异有统计学意义(P<0.05).治疗前,两组血清hs-CRP与MMP9比较,差异无统计学意义(P>0.05);治疗后两组hs-CRP与MMP9与治疗前比较均降低,且试验组低于对照组,差异有统计学意义(P<0.05).试验组与对照组药物不良反应比较,差异无统计学意义(P>0.05).结论瑞舒伐他汀联合贝那普利对高血压合并冠心病患者进行用药治疗,治疗价值高.

Objective To explore the effect of rosuvastatin combined with benazepril in the treatment of essential hypertension complicated with coronary heart disease.Methods A total of 70 patients with essential hypertension and coronary heart disease who were admitted to the hospital from February 2021 to October 2021 were selected and randomly divided into the control group and the experimental group with 35 cases in each group.Patients treated with benazepril were included in the control group,and the experimental group was treated with benazepril+rosuvastatin.The blood pressure,blood lipids,serum biochemical indexes and the incidence of adverse drug reactions were compared.Results There was no significant difference in diastolic blood pressure and systolic blood pressure between the two groups before treatment(P>0.05).The diastolic blood pressure and systolic blood pressure in the experimental group after treatment were lower than those in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of TC,TG,LDL-C and HDL-C between the two groups(P>O.05).After treatment,TC,TG and LDL-C in the two groups were lower than those before treatment,and HDL-C was higher than before treatment,and the experimental group was better than the control group,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in serum hs-CRP and MMP9 between the two groups(P>0.05).Statistical significance(P<0.05).There was no significant difference in adverse drug reactions between the experimental group and the control group(P>0.05).Conclusion Rosuvastatin combined with benazepril for the treatment of hypertension patients with coronary heart disease has high therapeutic value.